{"id":55650,"date":"2026-01-27T20:18:46","date_gmt":"2026-01-27T12:18:46","guid":{"rendered":"https:\/\/flcube.com\/?p=55650"},"modified":"2026-01-27T20:18:49","modified_gmt":"2026-01-27T12:18:49","slug":"nmpa-suspends-two-indian-pharma-apis-over-gmp-violations","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=55650","title":{"rendered":"NMPA Suspends Two Indian Pharma APIs Over GMP Violations"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">China\u2019s <strong>National Medical Products Administration (NMPA)<\/strong> announced enforcement actions against two India\u2011based active pharmaceutical ingredient (API) manufacturers following failed inspections, suspending import and domestic use of <strong>chlorpheniramine maleate<\/strong> from <strong>Supriya Lifescience Ltd.<\/strong> and <strong>rivastigmine hydrogen tartrate<\/strong> from <strong>Sun Pharmaceutical Industries Limited<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-inspection-outcomes-amp-enforcement-actions\">Inspection Outcomes &amp; Enforcement Actions<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Company<\/th><th>Product<\/th><th>Inspection Type<\/th><th>Violations<\/th><th>NMPA Action<\/th><\/tr><\/thead><tbody><tr><td><strong>Supriya Lifescience Ltd.<\/strong> (India)<\/td><td>Chlorpheniramine maleate API<\/td><td>On\u2011site<\/td><td>Inadequate batch compliance, facility management, pest control<\/td><td>Import and domestic use <strong>suspended<\/strong><\/td><\/tr><tr><td><strong>Sun Pharmaceutical Industries Ltd.<\/strong> (India)<\/td><td>Rivastigmine hydrogen tartrate API<\/td><td>Remote<\/td><td>Insufficient OOS risk assessment, corrective actions, contamination control, pharmacopeia compliance<\/td><td>Import, sale, use, and import clearance <strong>suspended<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-gmp-violations-amp-quality-failures\">GMP Violations &amp; Quality Failures<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-supriya-lifescience-chlorpheniramine-maleate\">Supriya Lifescience \u2013 Chlorpheniramine Maleate<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Batch Compliance:<\/strong> Failed to meet GMP and registration requirements, indicating systemic manufacturing control deficiencies<\/li>\n\n\n\n<li><strong>Facility Management:<\/strong> Inadequate infrastructure maintenance and operational oversight<\/li>\n\n\n\n<li><strong>Pest Control:<\/strong> Deficiencies in pest management systems compromising API purity and quality<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-sun-pharmaceutical-rivastigmine-hydrogen-tartrate\">Sun Pharmaceutical \u2013 Rivastigmine Hydrogen Tartrate<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Quality Management:<\/strong> Insufficient out\u2011of\u2011specification (OOS) risk assessment and inadequate corrective and preventive actions (CAPA)<\/li>\n\n\n\n<li><strong>Contamination Control:<\/strong> Failures in maintaining sterile processing environments<\/li>\n\n\n\n<li><strong>Pharmacopeia Compliance:<\/strong> Non\u2011compliance with Chinese Pharmacopoeia standards for API purity and impurity profiles<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-supply-chain-implications\">Market Impact &amp; Supply Chain Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Regulatory Enforcement:<\/strong> Actions reflect NMPA\u2019s heightened scrutiny of foreign API manufacturers amid China\u2019s push for supply chain security and quality assurance<\/li>\n\n\n\n<li><strong>Supply Disruption:<\/strong> Suspensions may impact domestic formulations dependent on these imported APIs, particularly generic antihistamines (chlorpheniramine) and Alzheimer\u2019s treatments (rivastigmine)<\/li>\n\n\n\n<li><strong>Indian Pharma Exposure:<\/strong> India supplies <strong>~40%<\/strong> of China\u2019s imported APIs; enforcement signals tighter GMP compliance demands<\/li>\n\n\n\n<li><strong>Domestic Substitution:<\/strong> Expected to benefit Chinese API manufacturers as drug makers seek alternative qualified suppliers<\/li>\n\n\n\n<li><strong>Precedent Setting:<\/strong> NMPA\u2019s use of <strong>remote inspections<\/strong> for API oversight establishes new enforcement model for international suppliers<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding supply chain impacts and regulatory enforcement trends. Actual results may differ due to remediation timelines, alternative supplier sourcing, and evolving NMPA inspection policies.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>China\u2019s National Medical Products Administration (NMPA) announced enforcement actions against two India\u2011based active pharmaceutical ingredient&#8230;<\/p>\n","protected":false},"author":1,"featured_media":55652,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[4],"tags":[4578],"class_list":["post-55650","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-policy-regulatory","tag-supriya-lifescience"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.8) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>NMPA Suspends Two Indian Pharma APIs Over GMP Violations - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China\u2019s National Medical Products Administration (NMPA) announced enforcement actions against two India\u2011based active pharmaceutical ingredient (API) manufacturers following failed inspections, suspending import and domestic use of chlorpheniramine maleate from Supriya Lifescience Ltd. and rivastigmine hydrogen tartrate from Sun Pharmaceutical Industries Limited.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=55650\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NMPA Suspends Two Indian Pharma APIs Over GMP Violations\" \/>\n<meta property=\"og:description\" content=\"China\u2019s National Medical Products Administration (NMPA) announced enforcement actions against two India\u2011based active pharmaceutical ingredient (API) manufacturers following failed inspections, suspending import and domestic use of chlorpheniramine maleate from Supriya Lifescience Ltd. and rivastigmine hydrogen tartrate from Sun Pharmaceutical Industries Limited.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=55650\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-27T12:18:46+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-27T12:18:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2714.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55650#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55650\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"NMPA Suspends Two Indian Pharma APIs Over GMP Violations\",\"datePublished\":\"2026-01-27T12:18:46+00:00\",\"dateModified\":\"2026-01-27T12:18:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55650\"},\"wordCount\":334,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55650#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/2714.webp\",\"keywords\":[\"Supriya Lifescience\"],\"articleSection\":[\"Policy \\\/ Regulatory\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=55650#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55650\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=55650\",\"name\":\"NMPA Suspends Two Indian Pharma APIs Over GMP Violations - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55650#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55650#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/2714.webp\",\"datePublished\":\"2026-01-27T12:18:46+00:00\",\"dateModified\":\"2026-01-27T12:18:49+00:00\",\"description\":\"China\u2019s National Medical Products Administration (NMPA) announced enforcement actions against two India\u2011based active pharmaceutical ingredient (API) manufacturers following failed inspections, suspending import and domestic use of chlorpheniramine maleate from Supriya Lifescience Ltd. and rivastigmine hydrogen tartrate from Sun Pharmaceutical Industries Limited.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55650#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=55650\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55650#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/2714.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/2714.webp\",\"width\":1080,\"height\":608,\"caption\":\"NMPA Suspends Two Indian Pharma APIs Over GMP Violations\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55650#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NMPA Suspends Two Indian Pharma APIs Over GMP Violations\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"NMPA Suspends Two Indian Pharma APIs Over GMP Violations - Insight, China&#039;s Pharmaceutical Industry","description":"China\u2019s National Medical Products Administration (NMPA) announced enforcement actions against two India\u2011based active pharmaceutical ingredient (API) manufacturers following failed inspections, suspending import and domestic use of chlorpheniramine maleate from Supriya Lifescience Ltd. and rivastigmine hydrogen tartrate from Sun Pharmaceutical Industries Limited.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=55650","og_locale":"en_US","og_type":"article","og_title":"NMPA Suspends Two Indian Pharma APIs Over GMP Violations","og_description":"China\u2019s National Medical Products Administration (NMPA) announced enforcement actions against two India\u2011based active pharmaceutical ingredient (API) manufacturers following failed inspections, suspending import and domestic use of chlorpheniramine maleate from Supriya Lifescience Ltd. and rivastigmine hydrogen tartrate from Sun Pharmaceutical Industries Limited.","og_url":"https:\/\/flcube.com\/?p=55650","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-27T12:18:46+00:00","article_modified_time":"2026-01-27T12:18:49+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2714.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=55650#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=55650"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"NMPA Suspends Two Indian Pharma APIs Over GMP Violations","datePublished":"2026-01-27T12:18:46+00:00","dateModified":"2026-01-27T12:18:49+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=55650"},"wordCount":334,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=55650#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2714.webp","keywords":["Supriya Lifescience"],"articleSection":["Policy \/ Regulatory"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=55650#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=55650","url":"https:\/\/flcube.com\/?p=55650","name":"NMPA Suspends Two Indian Pharma APIs Over GMP Violations - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=55650#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=55650#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2714.webp","datePublished":"2026-01-27T12:18:46+00:00","dateModified":"2026-01-27T12:18:49+00:00","description":"China\u2019s National Medical Products Administration (NMPA) announced enforcement actions against two India\u2011based active pharmaceutical ingredient (API) manufacturers following failed inspections, suspending import and domestic use of chlorpheniramine maleate from Supriya Lifescience Ltd. and rivastigmine hydrogen tartrate from Sun Pharmaceutical Industries Limited.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=55650#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=55650"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=55650#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2714.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2714.webp","width":1080,"height":608,"caption":"NMPA Suspends Two Indian Pharma APIs Over GMP Violations"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=55650#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"NMPA Suspends Two Indian Pharma APIs Over GMP Violations"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2714.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55650","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=55650"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55650\/revisions"}],"predecessor-version":[{"id":55653,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55650\/revisions\/55653"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/55652"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=55650"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=55650"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=55650"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}